CDMO/CMO

Radiopharmaceutical
CDMO/CMO

NorthStar Medical Radioisotopes is a leader in novel, domestic and environmentally preferred radioisotope development and production. Technologies that advance the availability of radiopharmaceuticals are increasingly critical for the treatment of cancer. NorthStar’s patient-focused Radiopharmaceutical Contract Development and Manufacturing Organization (CDMO/CMO) addresses this important need.

FROM DEVELOPMENT TO COMMERCIALIZATION

Our comprehensive services support collaborator companies by providing customized solutions to help navigate the complex radiopharmaceutical development and manufacturing process. NorthStar’s Radiopharmaceutical CDMO/CMO services span the spectrum of radioisotope drug development, from research and scale-up through commercialization, and all are designed to meet rigorous clinical trial and patient use requirements. Our proven expertise in innovation, engineering, manufacturing, quality assurance and quality control, adherence to regulatory standards, and logistics are applied to meet each customer’s specific needs.

R&D contract manufacturing services are currently available.

TIMELINE

Oct 2022
Facility Groundbreaking
Early 2023
Construction begins
June 2024
Construction complete
Jan 2025
CDMO/CMO Production Operations Launch

PARTNERING WITH
NORTHSTAR

For more information, please contact [email protected], and visit us here to learn about the continued progress of NorthStar’s Radiopharmaceutical CDMO/CMO.